Natalizumab Can Be Continued in JC Virus Antibody-Positive Patients
A positive JC virus antibody test is NOT a contraindication to continuing natalizumab (Tysabri) treatment. 1 The decision to continue should be based on a risk-stratified approach using the JCV antibody index value, treatment duration, prior immunosuppressant exposure, and intensive MRI monitoring protocols.
Risk Stratification Framework
The key is understanding that JCV antibody positivity alone does not determine PML risk—you must stratify by three critical factors 1:
- JCV antibody index value (≤1.5 vs >1.5)
- Duration of natalizumab therapy (particularly beyond 24 months)
- Prior immunosuppressant use
Quantified PML Risk by Index Value
For immunosuppressant-naïve patients 1:
- JCV antibody negative: 1 in 10,000 risk
- JCV antibody positive, index ≤1.5: 1 in 5,882 risk (months 1-24); 1 in 885 risk (months 25-48)
- JCV antibody positive, index >1.5: 1 in 855 risk (months 1-24); 1 in 113 risk (months 25-48)
Even with a high index (>1.5), many patients do not develop PML, though they require the most intensive monitoring 1.
Mandatory Monitoring Protocol for Continuation
If continuing natalizumab with positive JCV antibody status 1:
For Index ≤1.5:
- Test JCV antibody index every 6 months
- MRI at 12 months, then minimum 6-monthly after 18 months of treatment
- Use T2, DWI, and FLAIR sequences
For Index >1.5:
- Further index testing is not mandatory (manage based on highest value obtained)
- MRI at 12 months, then 3-4 monthly after 18 months of treatment
- More frequent scanning is critical—this is where PML can be detected 3-6 months before symptoms emerge 1
Additional Requirements:
- All MRI scans must be interpreted by a neuroradiologist trained in identifying PML 1
- Any new lesions not present on prior scans should trigger CSF analysis consideration 1
- Clinical vigilance remains paramount—monitoring protocols do not replace clinical judgment 1
Critical Caveats
Prior immunosuppressant use changes everything: If the patient has received prior immunosuppressants (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate) AND is JCV-positive AND/OR beyond 2 years of natalizumab, assume 3-4 monthly MRI frequency regardless of index value 1.
Index values can increase over time: Research shows anti-JCV antibody index tends to increase during natalizumab treatment 2, and once a patient reaches index >1.5, they should be managed as high-risk even if subsequent testing shows lower values 1. Always use the highest index value obtained for risk calculation 1.
Seroconversion occurs: Approximately 3-8% of JCV-negative patients seroconvert annually 3. If a patient converts from negative to positive during treatment, immediately revert to the monitoring schedule appropriate for their new index level 1.
Shared Decision-Making
The FDA label explicitly states that JCV antibody positivity is not a contraindication 3. The risks and benefits must be re-evaluated at appropriate intervals based on the patient's disease course and wishes 1. This means:
- Discuss the specific quantified PML risk based on their individual risk factors
- Explain the intensive monitoring requirements
- Consider MS disease activity and alternative treatment options
- Document that the patient understands and accepts the monitoring protocol
Research shows that despite JCV positivity causing elevated anxiety about PML, only approximately 3% of patients discontinue natalizumab solely due to positive serostatus 4, suggesting most patients find the benefit-risk ratio acceptable when properly counseled.
What NOT to Do
Do not automatically discontinue natalizumab based solely on JCV positivity—this contradicts expert guidelines 1 and may expose patients to MS rebound activity 5. The decision requires individualized risk assessment using the stratification algorithm above, not a blanket policy.